Inventprise is a mission driven vaccine manufacturing company developing vaccines that have shown a more robust and broader spectrum of protection than currently marketed conjugated vaccines. Our lead vaccine candidate is a 25-valent pneumococcal conjugate vaccine (PCV) funded by the Bill and Melinda Gates Foundation (>$100M) and aimed at large-scale supply to Low-Middle Income Countries. Additionally, we have a robust pipeline of vaccines and vaccine technologies, that have both viral and bacterial applications. Inventprise was founded in 2012, and is led by founder and Executive Chairman, Subhash Kapre PhD, former SVP and Corporate Officer of Serum Institute of India and Chief Executive Officer, Yves Leurquin, former general manager of Takeda Vaccines, Europe. Inventprise is based in Redmond, Washington, we have over 100,000 square feet of recently built, state-of-the-art facilities that have the capacity for large scale volume (>150M annual doses). With over 100 employees mostly exceptionally qualified industry scientists, and manufacturing professionals, Inventprise has created a large and dynamic presence in the Washington State Life Sciences environment.
May cause neonatal invasive diseases as well as severe infections in the elderly and immune-compromised patients. Despite significant advances in the prevention and treatment of neonatal diseases, sepsis and meningitis caused by GBS continue to represent a significant public health care concern globally. Additional prevention and therapeutic strategies against infection are highly desirable. IVT-GBS-6 has reached pre-clinical optimization and is supported with a $26M grant from the Bill and Melinda Gates Foundation.
Inventprise is currently funded by Bill & Melinda Gates Foundation (BMGF) to develop IVT-PCV-25, a third generation-25 valent pneumococcal conjugate vaccine (PCV) candidate. IVT-PCV-25 leverages our proprietary technology platform to provide the broadest coverage against pathogenic pneumococcal serotypes encountered by children. Each one of these serotypes has been carefully evaluated and determined to be critical for the protection of children under the age of 5 regardless of which country they live. IVT-PCV-25 will be indicated for active immunization for the prevention of invasive pneumococcal disease and otitis media.
The meningococcal vaccine market is diverse and complex with regional variations in serogroup distribution and significant use outside of routine immunization. The global supply of conjugate MenACWY is insufficient to meet demand growth triggered by rising incidence of serogroups C and W and the reduced availability of polysaccharide vaccines. Low and middle income countries struggle for access to multivalent and conjugate vaccines due to limited global access and high cost for conjugate vaccines. With this in consideration, our NMCV-4 program continues to be in development through self-funding.
Hia was recognized as an important pathogen causing severe infections in young children with a high case-fatality rate comparable to Hib disease before the introduction of pediatric immunization against the infection. Remarkably, the highest incidence rates of invasive Hia disease have been found in indigenous populations, such as North American Indians and Inuit of Alaska and Northern Canada. Hia has become the leading cause of bacterial meningitis among Native American children. Inventprise has partnered with the Canadian Government to fund development of a novel Hia vaccine
Yellow Fever Virus (VFV) infections are becoming a threat for global health due to vaccine shortages. Inventprise scientists are developing a next generation inactivated yellow fever vaccine based on cell culture technology. This will eliminate field reactions common with current egg-based vaccines, making the vaccine safer and a more viable option for travelers and other patients, as well as for international health organizations such as UNICEF and PAHO.
U.S. approved Rotavirus vaccines require cold chain storage. We’ve developed an innovative low volume (0.5 mL or less) oral rotavirus vaccine formulation which does not require refrigeration, and therefore is more stable, easier to administer, and reduces cold storage, transport and distribution costs. The new vaccine utilizes our patented technology to produce a thermostable formulation. This improves the release of live attenuated rotavirus into the intestine to provide immunity.
Our team is developing a novel acellular injectable pertussis vaccine. This involves establishing a method of making antigens, formulation of the end product, and the ability to stabilize the vaccine, allowing us to offer a high quality state of the art product to the global market including low and middle income countries..